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SUMMARY
Background
Hepatocellular carcinoma (HCC) causes premature death and loss of life
expectancy worldwide. Its primary and secondary prevention can result in a
signiﬁcant number of years of life saved.
Aim
To assess how many years of life are lost after HCC diagnosis.
Methods
Data from 5346 patients with ﬁrst HCC diagnosis were used to estimate
lifespan and number of years of life lost after tumour onset, using a semi-
parametric extrapolation having as reference an age-, sex- and year-of-
onset-matched population derived from national life tables.
Results
Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost
for each patient. The youngest age-quartile group (18–61 years) had the
highest number of years-of-life lost, representing approximately 41% of the
overall beneﬁt obtainable from prevention. Advancements in HCC manage-
ment have progressively reduced the number of years-of-life lost from
12.6 years in 1986–1999, to 10.7 in 2000–2006 and 7.4 years in 2007–2014.
Currently, an HCC diagnosis when a single tumour <2 cm results in
3.7 years-of-life lost while the diagnosis when a single tumour ≥2 cm or 2/
3 nodules still within the Milan criteria, results in 5.0 years-of-life lost, rep-
resenting the loss of only approximately 5.5% and 7.2%, respectively, of the
entire lifespan from birth.
Conclusions
Hepatocellular carcinoma occurrence results in the loss of a considerable
number of years-of-life, especially for younger patients. In recent years, the
increased possibility of effectively treating this tumour has improved life
expectancy, thus reducing years-of-life lost.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most
prevalent cancers worldwide, representing a frequent
cause of cancer-related deaths.1 It has currently shown
an increased incidence due the improved survival of
patients with chronic liver diseases and demographical
ageing.1, 2 Representing a leading cause of disability, its
diagnosis and treatment often include expensive proce-
dures which are capable of determining a substantial
impact on healthcare resources. Thus, a comprehensive
knowledge of the impact of HCC on population-mortal-
ity rates can give an accurate measure of the burden of
the disease. In Italy, the incidence of HCC is relatively
high.3 From National statistics, the number of new cases
per year is estimated to be about 13 200 (8900 male +
4300 female) in a population of 59.8 million of persons
and, for males aged between 50 and 69 years, HCC
ranks third as cause of death from cancers.4 A mild
higher incidence is observed in the South of Italy, mainly
related to the higher prevalence of hepatitis B and/or C
infection; however, the lower diffusion of surveillance
programmes in this area and the greater alcohol con-
sumption in North Italy returns a grossly similar number
of incident cases across the country.4
The epidemiological weight of cancer is ordinarily
measured in number of deaths, and reported as survival
rates. However, the number of years of life lost (YLL)
may be a more appropriate indicator of its impact on
society, since it represents a measure of relative survival
which takes into account the age at which the deaths
occur.5 Therefore, it gives greater weight to deaths at a
younger age than those occurring at an older age. Years
of life lost is a measurement used in public health to
compare the relative importance of different causes of
premature deaths in a given population, to establish pri-
orities for prevention and to compare the premature
mortality experience between populations.5, 6 It can pro-
vide not only an estimate of population-level effect but
also an effective health message for individuals who want
to clearly understand the severity of their disease.7, 8
This information is currently lacking for HCC, despite
the worldwide incidence of this cancer. In addition, the
estimation of YLL gives a precise measurement of the
impact of HCC on patient and population life expec-
tancy, and allows assessing its temporal trends regarding
demographic ageing, advances in the prevention, diagno-
sis and treatment of HCC, and liver diseases predispos-
ing to this cancer.
The aim of the present study was to assess YLL due
to HCC in a large cohort of adult patients diagnosed
with HCC in a setting of clinical practice. Temporal
trends and relationships with sex, age, tumour burden
and application of surveillance protocols were also
explored in order to understand how many years of life
could be saved by the prevention of an incident case of
HCC.
METHODS
Study population
The Italian Liver Cancer (ITA.LI.CA) database is a
prospective registry of HCC patients consecutively diag-
nosed with HCC between 1986 and 2014 who were fol-
lowed at 24 Italian medical institutions (North: 14;
Central: 6; South Italy: 4). Data entry was checked for
consistency by the group coordinator; when clariﬁcation
or additional informations were deemed necessary, rele-
vant cases were resubmitted to the recruitment centre
before ﬁnal inclusion in the database. The ITA.LI.CA
database management conforms to the past and the cur-
rent Italian legislation regarding privacy, and the present
study conforms to the ethical guidelines of the Declara-
tion of Helsinki. Approval for the study was obtained
from the Institutional Review Board of the participating
centers.
In December 2014, the ITA.LI.CA data set included
6581 HCC patients. The present study population
included only patients with a new HCC diagnosis, trea-
ted at participating centres with complete availability of
data regarding demographics (sex, age and year of diag-
nosis) and survival after diagnosis. Therefore, 933
patients were excluded because they were referred to
participating centres for cancer recurrence and 260
because they were referred after a poor response to ini-
tial therapies adopted in other care institutions. An
additional 42 patients were excluded due to incomplete
demographic or survival data. The ﬁnal cohort, anal-
ysed for lifespan and YLL estimates, was formed of
5346 patients with a newly diagnosed HCC. In this
sample, the presence of cirrhosis was histologically con-
ﬁrmed in only 19% of cases, whereas it was made
unequivocal in about 95% of the remaining subjects by
clinical, endoscopic and radiological signs together with
laboratory ﬁndings.
The following additional data were considered:
modality of HCC diagnosis (during or outside of
surveillance), number and diameter of lesions, Child–
Pugh class and ﬁrst-line therapy adopted. The tumour
burden was staged according to United Network for
Organ Sharing (UNOS) tumour staging and the Milan
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criteria.9, 10 The diagnosis of HCC was made according
to the guidelines published at the time of the cancer
detection. Liver function tests, alpha-fetoprotein levels
and tests for identifying the aetiology of liver
disease were determined by conventional methods using
commercially available assays. In each centre, the treat-
ment decisions were made by a multidisciplinary team,
taking into account tumour burden, liver function,
comorbidities and patient willingness. Several
therapeutic strategies were therefore used, including
resection, liver transplantation, percutaneous ablation,
trans-arterial embolisation (TAE), chemo-embolisation
(TACE), systemic therapies and best supportive care
(BSC).11
Statistical analysis
Continuous data were reported as means and standard
deviations (SDs) or medians and 95% conﬁdence inter-
vals (CIs) or interquartile ranges (IQRs) depending on
the distributions of the variables. Categorical data are
presented as counts and percentages. Differences in
means were investigated using the ANOVA test, and differ-
ences in percentages using the chi-square test; polyno-
mial linear contrast and linear-by-linear association were
used for trend analyses. Patient survival was measured
from the date of diagnosis until death or the date of the
last follow-up.
For a comprehensive interpretation of the results,
YLL estimates were reported before and after lead-time
bias correction of the survival of those patients diag-
nosed during surveillance. Lead-time is the time by
which the diagnosis is anticipated by screening with
respect to the clinical presentation of a disease and arti-
ﬁcially prolongs the survival of cases detected during
screening, leading to a specious improvement in progno-
sis with respect to symptomatic cases.11, 12 However, for
HCC patients the weight of lead-time bias becomes neg-
ligible for survival rates calculated 3 years after diagno-
sis.11 Therefore, the results of the present study,
encompassing the entire (extrapolated) post-diagnostic
lifespan, could be assumed as barely affected by this
bias. Nevertheless, they were reported both without and
after lead-time adjustment, which was obtained assum-
ing a tumour-doubling time of 100 days,11 an exponen-
tial tumour growth during the tumour sojourn time and
applying the formula proposed by Duffy et al.13 Statisti-
cal analyses were carried out using R-project (R Devel-
opment Core Team – 2008, R Foundation for Statistical
Computing, Vienna, Austria). A P < 0.05 was consid-
ered statistically signiﬁcant.
Extrapolation of years-of-life lost after cancer
diagnosis
The extrapolation of lifespan after tumour diagnosis
relies on the concept that HCC patients would die from
causes directly related to liver disease in addition to the
common causes experienced by the age- and sex-
matched general population, assuming a constant excess
hazard for the HCC cohort.14
First, an age-, sex- and year-of-diagnosis-matched
reference population was generated from population life
tables obtained from the Italian National Institute of
Statistics using the Monte Carlo method previously
described by Hwang and Wang.15, 16 Of note, Italian
national life tables report a life expectancy from birth
which increased linearly from 77 years in 1986 to the
current 83 years (80.4 for males and 85.6 years for
females).17 Second, knowing the survival of the cancer
cohort and that of the reference population at each time
t period, the survival ratio W (t) can be expressed as
S (t)HCC cohort/S (t)reference cohort.
14–16 For lifespan expec-
tancy extrapolation, W (t) was log-transformed: if the
cancer-associated excess hazard remains constant over
time, the logit of the W (t) curve would gradually pla-
teau over time, conﬁrming the existence of the constant
excess hazard and the reliability of the analysis (Fig-
ure S1). Third, a linear regression line to the logit of W
(t) to the end of the follow-up was ﬁtted and used to
predict a long-term survival curve, beyond the follow-up
limit of the HCC cohort. In this way, it was possible to
estimate the lifespan after tumour diagnosis of the HCC
cohort (up to 100 years old corresponding to
600 months).14–16 Finally, once the post-diagnosis lifes-
pan was obtained, YLL was calculated as the difference
in the area between the mean survival curves of the
HCC cohort and that of the reference population. The
ISQoL (integration of survival and quality of life) pack-
age for R-project was used for all the calculations; rela-
tive mathematical details have previously been described
elsewhere.14–16 The R-project package can be down-
loaded free from the following URL: http://www.s
tat.sinica.edu.tw/jshwang/isqol/
RESULTS
Baseline characteristics of the study population are
reported in Table 1. The mean age of the 5346 patients
was 67.1 years (s.d.: 10.0), ranging from 18 to 95 years,
having a median of 68 years. Male gender largely pre-
vailed (74.2%). The mean age for males was 65.9 years
(s.d.: 10.0) and for females was 70.5 (s.d.: 8.6;
P < 0.001). Four age quartiles were identiﬁed: 18–
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61 years (1419 patients), 62–68 years (1337 patients),
69–74 years (1287 patients) and 75–95 years (1303
patients). Four cohorts, based on the year of diagnosis,
were also generated: 1986–1992 (340 patients), 1993–
1999 (893 patients), 2000–2006 (1646 patients) and
2007–2014 (2467 patients).
The main cause of liver disease was hepatitis C infec-
tion (63.9%) and, in 62.9% of cases HCC was found in a
setting of well-preserved liver function (Child–Pugh class
A). Cancer was detected during a scheduled surveillance
in slightly more than half of the cases (55.3%). The
55.4% of patients were diagnosed with an HCC fulﬁlling
the Milan criteria (one single lesion ≤5 cm or no more
than three nodules each ≤3 cm, without vascular
invasion or extrahepatic spread). The majority of
patients underwent trans-arterial or percutaneous loco-
regional treatments, each of these approaches accounting
for about 30% of cases.
During a median follow-up of 20 months (range:
1 day–24 years) 3414 patients died (63.7%). Median sur-
vival of the entire cohort was 30 months (95% CI: 29–
31 months). The overall 1-, 3-, 5- and 10-year survival
rates were 75.9%, 45.9%, 28.4% and 13.9% respectively.
Years of life lost after tumour diagnosis
Calibration of the long-term survival model (Figure S1)
provided evidence for the constant excess hazard
assumption (this veriﬁcation was repeated for each sub-
group analysis). For the entire study cohort (Figure 1),
the estimated mean lifespan after tumour diagnosis was
4.9 years (95% CI: 4.3–5.4). The matched referent cohort
had a mean life expectancy of 16.4 years, resulting in a
number of YLL after tumour diagnosis of 11.5 years
(95% CI: 10.9–12.1). Detailed survival results and num-
ber of YLL, in relationship with age quartiles, sex and
year of diagnosis, are reported in Table 2. Notably,
1.0
0.8
0.6
Su
rv
iva
l
0.4
Reference general population
HCC cohort
0 100 200 300
Months
400 500 600
0.2
0.0
Figure 1 | The number of years of life lost (YLL)
estimation derives from the difference between the
area under the survival curve of the study population
formed by 5346 patients with ﬁrst diagnosis of
hepatocellular carcinoma (continuous line) and that of
the age-, year- and sex-matched reference population
derived from the Italian National Institute of Statistics
(dotted line).
Table 1 | Clinical characteristics of the whole
population (1986–2014) of HCC patients used for
estimation of years-of-life lost
Characteristics No. of patients
Age (years) (n = 5346)
Mean (s.d.) 67.1 (10.0)
Median (IQR) 68 (61–74)
18–61 years 1419 (26.5%)
62–68 years 1337 (25.0%)
69–74 years 1287 (24.1%)
75–95 years 1303 (24.4%)
Gender (n = 5346)
Male 3966 (74.2%)
Year of diagnosis (n = 5346)*
1986–1992 340 (6.4%)
1993–1999 893 (16.7%)
2000–2006 1646 (30.8%)
2007–2014 2467 (46.1%)
Hepatitis C infection (n = 5054)
Present 3227 (63.9%)
Hepatitis B antigen (n = 4816)
Positive 777 (16.1%)
Type of diagnosis (n = 5156)
Surveillance 2853 (55.3%)
Incidental 1536 (29.8%)
Symptoms 767 (14.9%)
Child–Pugh class (n = 4741)
A 2983 (62.9%)
B 1441 (30.4%)
C 317 (6.7%)
Tumour burden (n = 5266)
Single <2 cm 543 (10.3%)
Single 2–5 cm/2–3 nodules & Milan In 2373 (45.1%)
Single or multifocal & Milan Out 2350 (44.6%)
First-line therapy (n = 4645)
TACE/TAE 1486 (32.0%)
Ablation/Ethanol injection 1430 (30.8%)
BSC/Other 833 (17.9%)
Hepatic Resection 590 (12.7%)
Liver Transplantation 155 (3.3%)
Sorafenib 151 (3.3%)
* In the four periods the number of participating centres
increased as follows: 1986–1992 = 8; 1993–1999 = 12; 2000–
2006 = 18; 2007–2014 = 24. Geographical distribution of
patients was as follows: North Italy centres, n = 3922
(73.4%); Central Italy centres, n = 892 (16.7%); South Italy
centres, n = 532 (10.0%). The median number of patients
recruited for each centre was 176 (further details can be found
in the Appendix 1).
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younger patients had the highest estimated lifespan after
HCC diagnosis (6.9 years), but also the highest YLL
(19.1 years), the magnitude of which greatly exceeded
(12.2 years) estimated survival. All age groups showed
this imbalance which, however, progressively faded with
ageing so that, in patients over 75 years of age, the dif-
ference between lifespan and YLL was <2 years. Males
and females experienced similar number of YLL (12.0
and 11.0 years respectively). Temporal analysis showed
both a progressive increase in mean age at diagnosis
(P = 0.001) and a decrease in YLL, starting from year
2000 onwards.
Other temporal trends were investigated. Figure 2
shows a progressive decline in the use of TACE/TAE
over time (P = 0.001), mainly counterbalanced by an
increased use of ablative techniques (P = 0.038). Apart
from the availability of Sorafenib after 2007, no addi-
tional signiﬁcant differences in treatment allocation were
observed. Stratifying patients by Italian regions, it was
observed that in the last period (2007–2014) TACE was
adopted more frequently (33.1%) in the South Italy cen-
tres (recruited in recent years) as compared with both
North (29.0%) and Central Italy (19.3%) institutions,
already present in the ITA.LI.CA network (see the
Appendix 1 for details on the recruitment timing). This
could account for the plateau occurring in the last years,
following a gradual over time decrease in TACE utilisa-
tion (Figure 2).
Figure 3 shows that a progressive increase in
tumours diagnosed when single <2 cm or when single
2–5 cm or when 2–3 in number still fulﬁlling the
Milan criteria, was observed over the years (P = 0.001).
Figure 4 shows that surgery was most frequently
adopted among the youngest patients (P = 0.001),
whereas ablation techniques were preferred with ageing
patients (P = 0.001); TACE/TAE and other treatment
modalities did not show a signiﬁcant trend over age
quartiles.
Table 2 | Estimation of the entire lifespan after HCC diagnosis and number of years-of-life lost (YLL) with respect to
the general population (data released by the Italian National Institute of Statistics)
Mean age (s.d.)
Lifespan (years) after
diagnosis (95% CI)
Years of life lost
(95% CI)
Age
18–61 years (n = 1419) 54.2 (6.3) 6.9 (5.6–8.2) 19.1 (17.8–20.4)
62–68 years (n = 1337) 65.2 (1.9) 4.4 (3.8–4.9) 12.8 (12.2–13.3)
69–74 years (n = 1287) 71.5 (1.7) 4.0 (3.5–4.5) 9.0 (8.5–9.5)
75–95 years (n = 2467) 78.9 (3.5) 3.4 (2.9–3.8) 5.1 (4.7–5.6)
Males
All patients (n = 3966) 65.9 (10.1) 4.6 (4.2–5.0) 12.0 (11.5–12.4)
18–61 years (n = 1224) 53.9 (6.4) 6.2 (5.1–7.3) 19.4 (18.3–20.5)
62–68 years (n = 1025) 65.2 (1.9) 4.1 (3.6–4.6) 12.4 (11.9–12.9)
69–74 years (n = 888) 71.4 (1.7) 3.9 (3.5–4.3) 8.2 (7.8–8.6)
75–95 years (n = 829) 78.7 (3.3) 3.4 (2.9–3.9) 4.6 (4.0–5.1)
Females*
All patients (n = 1380) 70.5 (8.7) 5.1 (4.1–6.1) 11.0 (10.0–12.1)
18–68 years (n = 507) 55.6 (5.3) 6.0 (4.4–7.5) 17.2 (15.7–18.7)
69–74 years (n = 399) 65.2 (1.9) 4.7 (3.8–5.6) 10.2 (9.3–11.1)
75–95 years (n = 474) 71.6 (1.7) 3.2 (2.8–3.6) 6.4 (6.0–6.8)
Year of diagnosis†
1986–1992 (n = 340) 64.3 (9.0) 3.9 (3.1–4.7) 12.5 (11.7–13.3)
1993–1999 (n = 893) 64.7 (8.5) 4.1 (3.6–4.6) 12.7 (12.2–13.2)
2000–2006 (n = 1646) 67.1 (9.7) 5.7 (4.8–6.5) 10.7 (9.8–11.5)
2007–2014 (n = 2467) 68.4 (10.5) 8.9 (8.1–9.6) 7.4 (6.7–8.2)
For lead-time adjustment, a mean of 3.6 months (range 3.3–4.5 months) has to be subtracted from the total lifespan, or added
to the number of YLL, in each subgroup.
* The classes 18–61 years and 62–68 years were grouped because of the small size of each group resulting in unreliable esti-
mates.
† National life tables report a life expectancy from birth that linearly increased from 77 years in 1986 to the current 83 years:
80.4 for males and 85.6 years for females. The ANOVA test for mean age showed P = 0.642 between 1986–1992 and 1993–1999
and P = 0.001 from 2000 onwards having the ﬁrst period as a contrast.
Aliment Pharmacol Ther 5
ª 2016 John Wiley & Sons Ltd
Years of life lost from HCC diagnosis
As an additional ﬁnding, the proportion of patients
diagnosed under surveillance increased from 51.0% in
1986–1992 to 52.0% in 1993–1999, 55.1% in 2000–2006
and to 57.3% in 2007–2014 (P = 0.001). YLL were
calculated according to surveillance in the 1986–1999,
2000–2006 and 2007–2014 periods. In the ﬁrst period,
surveyed patients (n = 635) had 12.2 YLL (95% CI:
11.6–12.9) vs. 13.3 (95% CI: 12.8–13.8) of nonsurveyed
patients (n = 593) and in the 2000–2006 period, sur-
veyed patients (n = 852) had 9.9 YLL (95% CI: 8.9–10.8)
vs. 11.5 YLL (95% CI: 11.0–12.0) of nonsurveyed patients
(n = 694). In order to investigate today’s life expectancy
and YLL, all the analyses (including surveillance) were
repeated in the subset of patients with HCC diagnosed
between 2007 and 2014 (contemporary subset).
Years of life lost in the contemporary subset
Baseline characteristics of the 2467 HCC patients diag-
nosed between 2007 and 2014 are outlined in Table 3.
During a median follow-up of 16 months (range: 1
day–8 years), 1088 patients died (44.1%). The median
survival of this cohort was 34 months (95% CI: 31–37).
The overall 1-, 3-, 5- and 8-year survival rates were
76.4%, 49.2%, 33.3% and 26.0% respectively.
The YLL after tumour diagnosis were 7.4 (95% CI:
6.7–8.2). Lifespan estimates and the number of YLL, in
relationship with age class, sex, type of diagnosis and
tumour burden, are reported in Table 4. Once again,
the youngest patients experienced the highest number
of YLL, with males and females having similar ﬁgures.
Child–Pugh class A and surveilled patients had lower
YLL. In particular, YLL of surveyed patients was 6.2
(95% CI: 5.4–7.1) vs. 9.5 (95% CI: 8.4–10.6) of nonsur-
veyed patients. Of note, patients diagnosed with a sin-
gle HCC <2 cm and those diagnosed with a single
HCC 2–5 cm or with 2–3 nodules still fulﬁlling the
Milan criteria had the lowest ﬁgures of YLL (3.7 and
5.0 years respectively). No signiﬁcant differences were
observed among the three Italian regions (P = 0.774;
see Appendix 1)
DISCUSSION
The quantiﬁcation of lifespan after HCC diagnosis and
YLL represents advancement in the knowledge of the
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Figure 2 | Temporal trends in
the ﬁrst-line therapeutic
modalities adopted during the
study period (1986–2014). A
progressive decline in the use
of TACE/TAE over time was
observed (P = 0.001), mainly
counterbalanced by an
increased use of ablative
techniques (P = 0.038).
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Figure 3 | Stage migration
observed in the different time
spans. A progressive increase
in tumours diagnosed with
single <2 cm or with single 2–
5 cm or with 2–3 nodules
fulﬁlling the Milan criteria,
was observed over the years
(P = 0.001).
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impact of this cancer on patient survival. Reporting life
expectancy through these measures allows an immediate
and comprehensive health message to the community
regarding cancer outcome and the actual value of its pre-
vention.5
The present analysis showed that, over the last three
decades, the prevention of an incident case of HCC
could have saved an average of 12 years of life for each
patient. Unfortunately, although this ﬁgure is valuable,
the prevention of HCC is a very difﬁcult task.18 Primary
prevention includes the screening of blood products,
hepatitis B vaccination and policies aimed at reducing
alcohol intake and at promoting a correct lifestyle in
order to avoid non-alcoholic fatty liver disease (NAFLD)
in the general population. Secondary prevention has the
aim of slowing, or arresting, the progression of liver dis-
ease to cirrhosis, the main risk factor for HCC occur-
rence, through effective anti-viral therapies or the
correction of inappropriate eating, smoking and drinking
habits.18–20 In this regard, the recent advent of anti-viral
drugs able to cure hepatitis C in most cases will lead to
a great improvement in the life expectancy of patients
carrying this infection, due to an increased effectiveness
of the secondary prevention of liver cirrhosis and, conse-
quently, HCC.21
Several results of the present study require discussion.
First of all, the results make evident that younger indi-
viduals are the optimal target for primary and secondary
prevention of HCC since, despite the highest survival
after tumour diagnosis, they also experienced the highest
number of YLL (Tables 2 and 4). The value of prevent-
ing one HCC case in the ﬁrst six decades of life is higher
than that of preventing one case in subsequent decades.
The current possibility of saving 15.5 years of life in the
early decades of life (Table 4) surely has a greater social
impact than saving 4 or 10 years in older subjects.
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Figure 4 | Adoption of
different therapies by age
quartiles. Hepatic resection
was most frequently pursued
in the youngest patients
(P = 0.001), whereas ablation
techniques were preferred in
elderly patients (P = 0.001).
Table 3 | Clinical characteristics of the cohort of HCC
patients diagnosed between 2007 and 2014 used for
estimation of years-of-life lost in the most recent
recruitment period (contemporary subset)
Characteristics No. of patients
Age (years) (n = 2467)
Mean (s.d.) 68.4 (10.5)
Median (IQR) 70 (62–76)
18–61 years 588 (23.8%)
62–68 years 496 (20.1%)
69–74 years 619 (25.1%)
75–95 years 764 (31.0%)
Gender (n = 2467)
Male 1811 (73.4%)
Hepatitis C infection (n = 2391)
Present 1414 (59.1%)
Hepatitis B antigen (n = 2315)
Positive 777 (13.5%)
Child–Pugh class (n = 2301)
A 1429 (62.1%)
B 730 (31.7%)
C 142 (6.2%)
Type of diagnosis (n = 2382)
Surveillance 1366 (57.4%)
Incidental 699 (29.3%)
Symptoms 317 (13.3%)
Tumour Stage (n = 2429)
Single <2 cm 322 (13.3%)
Single 2–5 cm or 2–3 nodules & Milan In 1131 (46.5%)
Single/multifocal & Milan Out 976 (40.2%)
First-line therapy (n = 2151)
TACE/TAE 625 (29.1%)
Ablation/Ethanol injection 683 (31.8%)
BSC/Other 326 (15.2%)
Hepatic resection 288 (13.4%)
Liver transplantation 78 (3.6%)
Sorafenib 151 (7.0%)
Geographical distribution was as follows: North Italy centres,
n = 1455 (59.0%); Central Italy centres, n = 486 (19.7%);
South Italy centres, n = 526 (21.3%).
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Indeed, focusing on the 2007–2014 data, it can be calcu-
lated that the average YLL for the ﬁrst age quartile is
9114 years (15.5 9 588 patients), representing approxi-
mately 41% of the overall YLL (22 241 years). These
results can be interpreted from different standpoint: con-
sidering the perspective of the entire (from birth) lifes-
pan, it is reasonable that medical resources allocation,
rather than saving the most lives, should be aimed at
saving the most life-years in order to obtain similar life-
expectancies from birth for every individual (fulﬁlling
the concept of prudential lifespan account proposed by
the Nobel Prize philosopher Norman Daniels), without
incurring into ageism accusation.22, 23 Of note, this bene-
ﬁt was equal for males and females. There are two rea-
sons for the equivalence of YYL between genders;
females have a delayed peak incidence of HCC but also
a longer life expectancy in the general population.17
A second interesting ﬁnding is the decrease in YLL
observed in the new century (Table 2). This trend cannot
be attributed to older patient age at diagnosis since the
general population experienced a parallel increase in their
life expectancy.17 Instead, the favourable stage migration
phenomenon observed (Figure 3), attributable to the
increasing adoption of surveillance programmes, may
have played an important causative role.24 In particular,
in the latest time-period (2007–2015), the number of YLL
for very early tumours was very small (3.7 years) as well
as for early cases (5.0 years), representing the loss of only
approximately 5.5% and of 7.2% of the entire lifespan
(from birth) (Table 4). The improved therapeutic results
obtained in recent decades, especially with loco-regional
therapies which represent the most frequent ﬁrst-line
therapies adopted, have probably played an equally
important role. It is also worth noting that, among these
Table 4 | Estimation of entire lifespan after HCC diagnosis and numbers of years-of-life lost (YLL) in the cohort of
2467 patients diagnosed between 2007 and 2015. YLL were calculated using as reference life tables released by the
Italian National Institute of Statistics
Mean
age (s.d.)
Lifespan (years)
after diagnosis (95% CI)
Years of life
lost (95% CI)
Age
18–61 years (n = 588) 53.5 (6.6) 12.2 (10.0–14.4) 15.5 (13.3–17.7)
62–68 years (n = 496) 65.3 (1.9) 7.8 (6.4–9.1) 10.3 (8.9–11.7)
69–74 years (n = 619) 71.6 (1.7) 6.2 (5.0–7.3) 7.4 (6.3–8.6)
75–95 years (n = 764) 79.3 (3.6) 4.1 (3.4–4.9) 4.5 (3.8–5.2)
Males
All patients (n = 1811) 67.0 (10.7) 8.9 (7.9–9.8) 7.8 (6.8–8.7)
18–61 years (n = 513) 53.4 (6.5) 11.4 (8.9–14.0) 15.9 (13.4–18.4)
62–68 years (n = 395) 65.2 (1.9) 7.6 (5.8–9.5) 9.8 (7.9–11.6)
69–74 years (n = 423) 71.5 (1.7) 7.4 (6.3–8.4) 5.4 (4.3–6.5)
75–95 years (n = 480) 79.2 (3.5) 4.5 (3.4–5.6) 3.5 (2.5–4.6)
Females*
All patients (n = 656) 72.2 (8.9) 8.5 (7.1–9.9) 7.4 (6.0–8.7)
18–74 years (n = 372) 66.5 (7.5) 11.4 (9.5 – 13.3) 8.5 (6.5–10.4)
75–95 years (n = 284) 79.6 (3.8) 3.4 (2.9–3.8) 6.3 (5.8–6.8)
Child–Pugh class (n = 2301)
A (n = 1429) 69.0 (10.2) 7.4 (4.3–10.4) 8.4 (5.4–11.5)
B-C (n = 872) 67.6 (10.9) 3.7 (2.3–5.0) 13.4 (12.0–14.7)
Type of diagnosis (n = 2382)
Surveillance (n = 1366) 68.7 (10.0) 9.9 (9.0–10.8) 6.2 (5.4–7.1)
Incidental/symptoms (n = 1016) 68.0 (11.1) 7.1 (6.1–8.2) 9.5 (8.4–10.6)
Tumour burden (n = 2429)
Single <2 cm (n = 322) 67.0 (10.4) 13.8 (12.3–15.2) 3.7 (2.3–5.1)
Single 2–5 cm/2–3 & Milan In (n = 1131) 69.2 (9.9) 11.6 (10.8–12.4) 5.0 (4.1–5.8)
Single/multifocal & Milan Out (n = 976) 67.9 (11.0) 4.8 (4.0–5.5) 11.8 (11.0–12.5)
For lead-time adjustment, a mean of 3.7 months has to be subtracted from the total lifespan, or added to the number of YLL, in
each subgroup, ranging from zero (for incidental/symptomatic patients) to 5.8 months for patients diagnosed because of surveil-
lance.
* 18–61, 62–68 and 69–74 year classes were grouped together because the small size of each group did not result in reliable esti-
mates.
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therapies, the curative approach (ablation) has surpassed
the palliative one (TACE) in recent years (Figure 2).
Moreover, surgical advances, reﬁned retreatment sched-
ules using the same or different approaches and the avail-
ability of sorafenib have likely contributed to reducing the
YLL in the latest time period. All in all, smaller tumours
at diagnosis, which are more efﬁciently treatable with all
therapeutic strategies and reﬁnements of therapies, have
resulted in decreasing YLL after HCC diagnosis.
A ﬁnal brief discussion should be reserved as to what
is already known about the subject of the present study.
A 2013 report from the Surveillance, Epidemiology and
End Results (SEER) program including six different types
of cancers, quotes an estimated number of YLL of
16.7 years for ‘liver cancer’.25 This ﬁgure is different
from the present ﬁndings, especially considering that the
average life expectancy of the US population is lower
than that of the Italian population.26 This difference may
have two explanations. First, in deﬁning ‘liver cancer’
authors have probably included not only HCCs but
also tumours of the biliary tract which have a worse
prognosis, thus increasing the number of YLL. Second,
our data were generated in centres where expertise
regarding HCC management can be considered high.
Indeed, all the ITA.LI.CA centres are experts in the man-
agement of liver diseases and operate in a setting of collabo-
rative multidisciplinary regional/supraregional networks
which include tertiary referral centres (high volume cen-
tres) and liver transplant units. Despite the trend toward a
more frequent adoption of TACE in South Italy, no signiﬁ-
cant regional differences in YLL were observed and all these
features can explain the better YLL ﬁgures observed in the
present study in respect to the SEER results. Although
based on a very large sample size, the present study is not
population-based, but this inherent limitation should be
viewed in the light of the complementary utility between
population-based statistics and large clinical-based studies,
which can provide many more (and veriﬁed) data for the
analyses. Moreover, to the best of our knowledge, the ITA.-
LI.CA registry is the largest, multicentric, permanent data-
base of HCC patients available in Europe, adding value to
the present results.
Our results should be also interpreted in the light of
those generated by country-speciﬁc population-based
statistics. In Italy, the Global Burden of Disease Study
currently shows that ischaemic heart disease and cerebro-
vascular disease still represent the leading causes of death
accounting for about 25% of the total YLL through popu-
lation, with a considerable reduction (more than 30%)
through the last decades, due to medical improvements.27
Lung and breast cancers, among within the ﬁrst seven
causes of YLL, also showed a reduction in about 20% of
the total YLL. Conversely, liver cancer showed an increase
in about 16% of the total YLL moving this cancer within
the ﬁrst 10 causes of YLL in more recent period. Present
results indicate that even if HCC is not the leading causes
of YLL in the whole population, it currently represents a
major health problem in Italy,4
The present study has at least two potential limita-
tions due to methodological aspects. First, the lifespan
calculation is based on the projection of a survival curve,
therefore representing an estimated result (based on real-
life data) but not an observed result. The most robust
method for calculating YLL would rely on observing the
cohort until all patients had died. However, this would
require an extremely long follow-up, leading to a high
risk of resulting in a ﬁgure which would be out-of-date
at the time of the assessment. The delayed availability of
data sharply contrasts with the need to promptly adapt
the available resources to the current clinical scenario
and its temporal trends. It should also be considered that
the mathematical approach adopted in this study is
reported to suffer from a very small imprecision
(1.5%) with respect to the entire observed lifespan.25
Second, the YLL estimate is affected not only by the sur-
vival of the HCC cohort but also by the life expectancy
of the reference cohort. Therefore, since the life expec-
tancy of the reference population is inﬂuenced by the
cancer itself, the YLL may have been underestimated.
However, it is likely that this unavoidable bias was mini-
mal, because a single cancer has a relatively small effect
on the life tables of the general population which include
all causes of death. Two ancillary methodological limita-
tions rely on the impossibility, through present estimates,
to: (i) assess the competing role of each prognostic factor
in determining survival and YLL (i.e. multivariate analy-
sis); (ii) calculate robust disability-adjusted life years
saved. We attempted to overcome the ﬁrst problem per-
forming subanalyses after several patient stratiﬁcations
but, for a comprehensive investigation of inter-relation-
ships between variables, a new analytic (multivariable)
approach would be required that, to the best of our
knowledge, is currently not available. Second, the calcu-
lation of the quality-adjusted life expectancy in HCC
cohorts would be of interest, but it relies on the avail-
ability of data regarding quality of life (utilities). Popula-
tion-based statistics report disability-adjusted YLL, based
on rough estimates of utilities.27 However, for HCC
patients, the quality of life changes not only according to
the stage of underlying liver disease (pre-cirrhotic dis-
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ease, compensated and decompensated cirrhosis) but also
with the treatment adopted.28, 29 These health states can-
not be considered as a unique utility and the possible
solution to obtain a comprehensive disability-adjusted
YLL estimation is to build a dedicated multistage Mar-
kov model.
In conclusion, the present results offer a novel measure-
ment of health care communication in the ﬁeld of HCC,
that is primary and secondary prevention of this tumour
could have saved, on average, 12 years of life for each case
prevented in the last decades. The increasing use of
surveillance of patients at risk of HCC, and the advance-
ment in and the management of this cancer has currently
reduced this loss to 7.4 years. Moreover, it can be esti-
mated that today a diagnosis of HCC at an early stage can
guarantee the patient an entire lifespan (i.e. from birth)
close to that of the general population.
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(t) between the survival function of the 5346 patients form-
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diagnosis) while the horizontal dotted line is the slope of
the logit survival ratio. The process was repeated for each
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